Weiling Medical

Weiling Medical (微灵医疗) is a Shenzhen-based brain-computer interface (BCI) startup founded in April 2019 by Li Xiaojian, a senior engineer at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences . The company develops medical-grade fully implantable wireless BCI systems, positioning itself as one of the few teams globally with full-chain autonomous technology covering the entire implantable BCI pipeline from sensors to chips to software .

Its hardware stack includes high-density ultra-compliant neural sensor arrays, acquisition-and-stimulation integrated closed-loop neural chips, thousand-channel neural signal acquisition systems, and wireless brain-information transceivers; software covers preprocessing, decoding, and brain-inspired control algorithms . A distinctive technical choice is its surface electrode approach—arrays that attach to the brain cortex without penetrating tissue, which the company argues avoids the single-lifetime limitation of penetrating electrodes . The team also pioneered "non-genetic optical nano-neural remote control technology," with results published in *Nature* journals in 2018, 2019, and 2023 .

The company has raised two disclosed rounds: an angel round of several tens of millions of yuan in early 2023, co-led by BlueRun Ventures and CDH Investments ; and an angel-plus round in late 2023 led by Gaorong Ventures, with follow-on from CDH and new backers including Qiji Investment . BlueRun Ventures has continued to list Weiling Medical among its portfolio companies as of early 2025 . The funding has been directed toward clinical validation of its implantable systems, chip finalization, and bidirectional neural regulation technology .